Education
About Us
Working with TipRanks
Follow Us
Cognition Therapeutics (CGTX)
NASDAQ:CGTX
Total Valuation
Cognition Therapeutics has a market cap or net worth of $23.75M. The enterprise value is -$2.49M.
Market Cap$23.75M
Enterprise Value-$2.49M
Share Statistics
Cognition Therapeutics has 61.97M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61.97M
Owned by Insiders22.36%
Owned by Instutions0.11%
Financial Efficiency
Cognition Therapeutics’s return on equity (ROE) is -1.81 and return on invested capital (ROIC) is -279.83%.
Return on Equity (ROE)-181.18%
Return on Assets (ROA)-112.36%
Return on Invested Capital (ROIC)-279.83%
Return on Capital Employed (ROCE)-282.66%
Revenue Per Employee$0
Profits Per Employee-$1,358,840
Employee Count25
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cognition Therapeutics is -0.82. Cognition Therapeutics’s PEG ratio is 0.00.
PE Ratio-0.82
PS Ratio0.00
PB Ratio1.49
Price to Fair Value1.49
Price to FCF-0.98
Price to Operating Cash Flow-0.98
PEG Ratio0.00
Income Statement
In the last 12 months, Cognition Therapeutics had revenue of $0.00 and earned -$33.97M in profits. Earnings per share was -$0.90.
Revenue$0.00
Gross Profit-$125.00K
Operating Income-$53.97M
Pretax Income-$33.97M
Net Income-$33.97M
EBITDA-33.68M
Earnings Per Share (EPS)-0.90
Cash Flow
In the last 12 months, operating cash flow was -$28.47M and capital expenditures -$1.00K, giving a free cash flow of -$28.48M billion.
Operating Cash Flow-$28.47M
Free Cash Flow-$28.48M
Free Cash Flow per Share-$0.46
Dividends & Yields
Cognition Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-102.19%
Earnings Yield-121.92%
Stock Price Statistics
Beta1.83
52-Week Price Change-79.89%
50-Day Moving Average0.46
200-Day Moving Average0.68
Relative Strength Index (RSI)42.59
Average Volume (3m)628.47K
Important Dates
Cognition Therapeutics upcoming earnings date is May 7, 2025, Before Open.
Last Earnings DateMar 20, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Cognition Therapeutics as a current ratio of 2.65, with Debt / Equity ratio of 0.03
Current Ratio2.65
Quick Ratio2.65
Debt to Market Cap0.02
Net Debt to EBITDA0.45
Interest Coverage Ratio2.16K
Taxes
In the past 12 months, Cognition Therapeutics has paid $14.72K in taxes.
Income Tax$14.72K
Effective Tax Rate0.00%
Enterprise Valuation
Cognition Therapeutics EV to EBITDA ratio is -0.06, with an EV/FCF ratio of -0.12.
EV to Sales0.00
EV to EBITDA-0.06
EV to Free Cash Flow-0.12
EV to Operating Cash Flow-0.12
Balance Sheet
Cognition Therapeutics has $25.01M in cash and marketable securities with $814.00K in debt, giving a net cash position of -$24.20M billion.
Cash & Marketable Securities$25.01M
Total Debt$814.00K
Net Cash-$24.20M
Net Cash Per Share-$0.39
Tangible Book Value Per Share$0.47
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Cognition Therapeutics is $5.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$5.50
Price Target Upside1386.49%
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast
EPS Growth Forecast-0.38%